Health related Quality of Life over time in German sarcoma patients. An analysis of associated factors - results of the PROSa study

Frontiers in Endocrinology

Endocrinology

Markus K. Schuler¹  Stephan Richter¹  Martin Bornhäuser²  Martin Eichler²  Helena K. Jambor²  Marius Fried³  Stephen Fung⁴  Robert Grützmann⁵  Dimosthenis Andreou⁶  Peter Hohenberger⁷  Jens Jakob⁸  Eva Wardelmann⁹  Karin Arndt^1,10  Susanne Singer^1,11  Beate Hornemann^1,12  Leopold Hentschel^1,12  Jochen Schmitt^1,13  Olaf Schoffer^1,13  Jürgen Weitz^1,14  Christine Hofbauer^1,15  Klaus-Dieter Schaser^1,15  Daniel Pink^1,16  Bernd Kasper^1,17  Kerstin Hermes-Moll^1,18 

[1] Clinic and Polyclinic for Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany;Clinic and Polyclinic for Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany;National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany;Helmholtz-Center Dresden-Rossendorf (HZDR), Dresden, Germany;Clinic and Polyclinic for Internal Medicine III/University Cancer Center Mainz, University Hospital Mainz, Mainz, Germany;Clinic for General, Visceral, and Pediatric Surgery, University Hospital Dusseldorf, Dusseldorfn, Germany;Clinic for Surgery, University Hospital Erlangen, Erlangen, Germany;Department of General Orthopedics and Tumor Orthopedics, Münster University Hospital, Münster, Germany;Department of Orthopedics and Trauma, Medical University of Graz, Graz, Austria;Division of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany;Division of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany;Clinic for General, Visceral, and Pediatric Surgery, University Hospital Goettingen, Goettingen, Germany;Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany;German Sarcoma Foundation, Woelfersheim, Germany;Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centre of Johannes Gutenberg University Mainz, Mainz, Germany;National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany;Helmholtz-Center Dresden-Rossendorf (HZDR), Dresden, Germany;National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany;Helmholtz-Center Dresden-Rossendorf (HZDR), Dresden, Germany;Center for Evidence-based Healthcare, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany;National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany;Helmholtz-Center Dresden-Rossendorf (HZDR), Dresden, Germany;Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany;National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany;Helmholtz-Center Dresden-Rossendorf (HZDR), Dresden, Germany;University Center for Orthopedics and Trauma Surgery, Technical University Dresden, Dresden, Germany;Sarcoma Center Berlin-Brandenburg, Helios Hospital Bad Saarow, Bad Saarow, Germany;Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany;Sarcoma Unit, Mannheim Cancer Center, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany;Scientific Institute of Office-based Hematologists and Oncologists, Cologne, Germany;

关键词: sarcoma;    GIST;    health-related quality of life;    patient reported outcomes;    EORTC QLQ-C30;    longitudinal observational cohort;   

DOI  :  10.3389/fendo.2023.1166838

 received in 2023-02-15, accepted in 2023-08-01,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionSarcomas are rare cancers and very heterogeneous in their location, histological subtype, and treatment. Health-Related Quality of Life (HRQoL) of sarcoma patients has rarely been investigated in longitudinal studies.MethodsHere, we assessed adult sarcoma patients and survivors between September 2017 and February 2020, and followed-up for one year in 39 study centers in Germany. Follow-up time points were 6 (t1) and 12 months (t2) after inclusion. We used a standardized, validated questionnaire (the European Organisation for Research and Treatment of Cancer Quality of Life Core Instrument (EORTC QLQ-C30) and explored predictors of HRQoL in two populations (all patients (Analysis 1), patients in ongoing complete remission (Analysis 2)) using generalized linear mixed models.ResultsIn total we included up to 1111 patients at baseline (915 at t1, and 847 at t2), thereof 387 participants were in complete remission at baseline (334 at t1, and 200 at t2). When analyzing all patients, HRQoL differed with regard to tumor locations: patients with sarcoma in lower extremities reported lower HRQoL values than patients with sarcomas in the upper extremities. Treatment which included radiotherapy and/or systemic therapy was associated with lower HRQoL. For patients in complete remission, smoking was associated with worse HRQoL-outcomes. In both analyses, bone sarcomas were associated with the worst HRQoL values. Being female, in the age group 55-<65 years, having lower socioeconomic status, and comorbidities were all associated with a lower HRQoL, in both analyses.DiscussionHRQoL increased partially over time since treatment and with sporting activities. HRQoL improved with time since treatment, although not in all domains, and was associated with lifestyle and socioeconomic factors. Bone sarcomas were the most affected subgroup. Methods to preserve and improve HRQoL should be developed for sarcoma patients.

【 授权许可】

Unknown   
Copyright © 2023 Eichler, Hentschel, Singer, Hornemann, Richter, Hofbauer, Hohenberger, Kasper, Andreou, Pink, Jakob, Grützmann, Fung, Wardelmann, Arndt, Hermes-Moll, Schoffer, Fried, Jambor, Weitz, Schaser, Bornhäuser, Schmitt and Schuler